Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [839]

The importance of target expression in personalised medicine

Dr Paolo Nuciforo - Vall d'Hebron Institute of Oncology, Barcelona, Spain

The importance of target expression in personalised medicine ( Dr Paolo Nuciforo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL...

Dr Paula Cramer - University of Cologne, Köln, Germany

Ibrutinib combined with bendamustine plus rituximab in previously treated CLL and SLL ( Dr Paula Cramer - University of Cologne, Köln, Germany )

TAT 2016: Targeted anticancer therapies

Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA

TAT 2016: Targeted anticancer therapies ( Dr Giuseppe Giaccone - Georgetown University Medical Center, Washington, USA )

EHA 2015 highlights

Peter Goodwin - ecancer reporter

EHA 2015 highlights ( Peter Goodwin - ecancer reporter )

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid...

Prof Susan Branford - Adelaide University Adelaide, Australia

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia ( Prof Susan Branford - Adelaide University Adelaide, Australia )

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

DNMT3A R882 mutations promote chemoresistance and residual disease in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

Expert overview on the recent developments in mantle cell lymphoma

Professor Gordon McVie and Professor Simon Rule

Expert overview on the recent developments in mantle cell lymphoma ( Professor Gordon McVie and Professor Simon Rule )

Round-up of the latest research on lung cancer

Dr James Spicer - Guy's Hospital, London, UK

Round-up of the latest research on lung cancer ( Dr James Spicer - Guy's Hospital, London, UK )

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma

Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma ( Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy )

Nivolumab alone superior to ipilimumab alone in advanced melanoma

Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy

Nivolumab alone superior to ipilimumab alone in advanced melanoma ( Dr Pier Francesco Ferrucci - European Institute of Oncology, Milan, Italy )

Adjuvant denosumab may preserve bone health in postmenopausal breast cancer...

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Adjuvant denosumab may preserve bone health in postmenopausal breast cancer patients: results of the ABCSG-18 trial ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )

Initial nivolumab-based treatment halts melanoma progression

Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Initial nivolumab-based treatment halts melanoma progression ( Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA )

More from ecancer